"..blinded evaluators were able to identify accurately the RXI-109 treated site at the 3-month follow-up more frequently (54%) than when treatment was initiated immediately post scar revision surgery (24%) (p< 0.0001 Fisher exact 2-tailed)."
54% doesn't sound like enough at this point. Barely half. That's close to the odds of a coin flip/guessing.
From the chart, the market doesn't seem impressed either. No reaction.
News 
Market Data 
Discover 
